Publication Only: Myeloma and other monoclonal gammopathies - Clinical
The standard treatment for multiple myeloma (MM) which ineligible transplant is melphalan prednisone (MP). Curcumin has anti-inflamatory, anti angiogenesis, decrease proliferation and delay progression of monoclonal gammopathy undetermined significant or smoldering myeloma. There is no study of curcumin in MM patients
To evaluate the effect of curcumin addition to remission status at MM patient with regiment MP
This experimental study was involved 35 patients which randomly into treatment (n = 17) and control (n = 16). The treatment group was given melphalan 4 mg/m2, prednisone 40 mg/m2 (MP) for 7 days and curcumin 8 gram daily for 28 days. The control group was given MP and placebo. Remision status was evaluated after 4 cycles treatment. The difference between two groups was analysed by Mann-Whitney U-Test. Trend analysis was evealuated by Friedman. Remission status was evaluated by Chi-square. Multivariate analysis was evaluated by multiple logistic regression.
There was a significant decrease of NF-KB, VEGF, TNF-α, LDH levels in the treatment group compared with control. There was a decreasing trend of IL-6 levels in the treatment group significantly. There was significant difference of remission status beetween the treatment and control group [(75 vs 33.3), X2 = 6.89,df = 1, p = 0.009]. There was significant correlation between TNF-α levles and remission status [OR = 1.35; (95% CI = 1.03-1.7.6), p = 0.03].
The curcumin addition on MM patient with MP regiment improved the remision status through decreased of TNF-α levels.